Short answer
Bruker Corp (BRKR) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Board expansion from 11 to 12 directors, increasing governance capacity.
Bruker Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expansion from 11 to 12 directors, increasing governance capacity
- Eicke Latz MD PhD joins effective January 1, 2027, serving Class II through the 2029 Annual Meeting
- Standard non-employee director compensation, with no disclosed related-party transaction
- Committee assignments pending, limiting near-term visibility into his oversight responsibilities
Item 8.01 · Other Events
- Quarterly cash dividend: $0.05 per common share
- Payable January 7, 2027, to shareholders of record December 21, 2026
- Dividend declaration signals continued shareholder-return commitment by Bruker’s board
Item EX-99.1 · Exhibit EX-99.1
- Dr. Eicke Latz joining Bruker’s board effective January 1, 2027
- Scientific leadership in innate immunity, inflammation, proteomics, and molecular diagnostics
- Co-founder of five biotechnology companies, including IFM Therapeutics and Odyssey Therapeutics
- Board appointment strengthens Bruker’s biopharma, disease-biology, and drug-discovery expertise
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bruker Corp 8-K filings
Get the next BRKR 8-K as it lands
Follow BRKR for push alerts, or ask the research agent what this filing means.